Drug intelligence / Profile preview

cisplatin + rintatolimod + interferon alpha + celecoxib + alpha-type-1-polarized dendritic cell vaccine

Development stage: Unknown
Lead developer: UPMC Hillman Cancer Center
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intraperitoneal, Oral, Intradermal, Intranodal

Overview

Cisplatin + CKM + celecoxib + DC vaccine is an investigational chemo-immunotherapy combination regimen developed by the Roswell Park Comprehensive Cancer Center for the treatment of advanced-stage ovarian cancer. The regimen is designed to reprogram the tumor microenvironment (TME) from an immunosuppressive state to one that favors the infiltration and activity of cytotoxic T lymphocytes (CTLs). It consists of four primary components: intraperitoneal cisplatin (a DNA-alkylating chemotherapy), a chemokine modulatory (CKM) regimen comprising rintatolimod (a TLR3 agonist) and interferon-alpha (IFNα), oral celecoxib (a COX-2 inhibitor), and an autologous alpha-type-1-polarized dendritic cell (alpha-DC1) vaccine. By combining these agents, the therapy aims to increase the production of CTL-attracting chemokines (such as CXCL9 and CXCL10) while suppressing regulatory T cell (Treg)-attracting signals (such as CCL22) and prostaglandin E2 (PGE2) production. This multi-pronged approach is currently being evaluated in Phase 1/2 clinical trials for patients with recurrent or advanced ovarian cancer.

Brand names: PlatinolPlatinol-AQCelebrex
Other names: cisplatin + CKM + celecoxib + DC vaccineIPC-CKM + alphaDC1 vaccinecisplatin + CKM + celecoxib + alpha-DC1 vaccine

Targets

TLR3 (Toll-like receptor 3)IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR (Immune system modulation via type I interferon receptor)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)DNA

Beyond the preview

Go deeper on cisplatin + rintatolimod + interferon alpha + celecoxib + alpha-type-1-polarized dendritic cell vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cisplatin + rintatolimod + interferon alpha + celecoxib + alpha-type-1-polarized dendritic cell vaccine.

Explore the full profile